Src-JNK Potentiation of Estrogen Receptor AF-1; Mechanism, and Role in Estrogen Action in Breast Cancer

2001 ◽  
Author(s):  
Peter J. Kushner
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Estrogen Action

Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer

2007 ◽  
Vol 25 (36) ◽  
pp. 5815-5824 ◽  
Author(s):  
V. Craig Jordan ◽  
Bert W. O'Malley
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endometrial Cancer ◽  
Growth Factor Receptor ◽  
The Body ◽  
Breast Cancers ◽  
Estrogen Action ◽  
High Risk Women ◽  
Estrogen Receptor Modulators ◽  
Target Sites

Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen action by binding to the ER in breast cancers. Tamoxifen has been used ubiquitously in clinical practice during the last 30 years for the treatment of breast cancer and is currently available to reduce the risk of breast cancer in high-risk women. Raloxifene maintains bone density (estrogen-like effect) in postmenopausal osteoporotic women, but at the same time reduces the incidence of breast cancer in both high- and low-risk (osteoporotic) postmenopausal women. Unlike tamoxifen, raloxifene does not increase the incidence of endometrial cancer. Clearly, the simple ER model of estrogen action can no longer be used to explain SERM action at different sites around the body. Instead, a new model has evolved on the basis of the discovery of protein partners that modulate estrogen action at distinct target sites. Coactivators are the principal players that assemble a complex of functional proteins around the ligand ER complex to initiate transcription of a target gene at its promoter site. A promiscuous SERM ER complex creates a stimulatory signal in growth factor receptor–rich breast or endometrial cancer cells. These events cause drug-resistant, SERM-stimulated growth. The sometimes surprising pharmacology of SERMs has resulted in a growing interest in the development of new selective medicines for other members of the nuclear receptor superfamily. This will allow the precise treatment of diseases that was previously considered impossible.

Androgen and Estrogen Receptor Co-regulation of Human UDP-glucuronosyltransferases 2B15 and 2B17 in Breast Cancer

2016 ◽  
Author(s):  
Dong Gui Hu ◽  
Luke Selth ◽  
Gerard Tarulli ◽  
Robyn Meech ◽  
Dhilushi Wijayakumara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor
Sign in / Sign up

Export Citation Format

Share Document